Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Irinotecan for ctDNA Positive Colon Adenocarcinoma
NCT04920032Phase 1Recruiting
- Sponsor
- University of California, Irvine
- Start
- Aug 2021
- Primary completion
- Jan 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon adenocarcinoma, sponsored by University of California, Irvine. Primary endpoint: Percentage of ctDNA positivity at 6 months. Started Aug 2021; status: recruiting.
02
Drugs
trifluridine + tipiracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on NCT04920032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920032.